Progress in systemic therapy for advanced-stage urothelial carcinoma

Area of Science:

• Oncology
• Immunotherapy
• Urothelial Carcinoma Research

Background:

• Advanced-stage urothelial carcinoma (aUC) has a poor prognosis with a 5-year survival rate around 10%.
• Platinum-based chemotherapy is a standard first-line treatment for most aUC patients.
• Recent approvals have introduced new therapeutic options, improving survival outcomes.

Purpose of the Study:

• To review the evolution of systemic therapies for advanced-stage urothelial carcinoma.
• To highlight recent therapeutic advancements and their impact on patient outcomes.
• To identify unmet needs and future directions in aUC treatment.

Main Methods:

• Review of current literature on systemic therapies for advanced-stage urothelial carcinoma.
• Analysis of recent clinical trial outcomes and drug approvals.
• Discussion of emerging treatment modalities and ongoing research questions.

Main Results:

• Avelumab (anti-PD-L1) maintenance therapy has improved survival for patients without initial progression on chemotherapy.
• First-line immune-checkpoint inhibitors (ICIs) are mainly for platinum-ineligible patients.
• Newer agents like enfortumab vedotin, pembrolizumab, and sacituzumab govitecan show promise in various treatment settings.

Conclusions:

• Significant progress has been made in advanced urothelial carcinoma systemic therapy.
• Key challenges include the need for predictive biomarkers and optimized treatment sequencing.
• Future research directions involve antibody-drug conjugates, next-generation ICIs, bispecific antibodies, and cellular therapies.